- Trials with a EudraCT protocol (123)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
123 result(s) found for: Bipolar I disorder.
Displaying page 1 of 7.
EudraCT Number: 2015-004872-31 | Sponsor Protocol Number: SCA102833 | Start Date*: 2016-12-21 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003972-42 | Sponsor Protocol Number: A1281198 | Start Date*: 2020-08-21 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPO... | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004088-26 | Sponsor Protocol Number: A1281201 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC) | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002778-30 | Sponsor Protocol Number: GR-2018-12367476 | Start Date*: 2022-01-12 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: Efficacy and safety of memantine as antimanic and mood-stabilizing medication for adolescents with Bipolar Disorder: a multi-center, randomized, double-blind, placebo-controlled clinical trial | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023740-32 | Sponsor Protocol Number: 2010-023740-32 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Haukeland University Hospital [...] | |||||||||||||
Full Title: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder | |||||||||||||
Medical condition: The goal of this work is to identify genes associated with good response of bipolar patients to two commonly used mood stabilizing agents, lithium and valproate. 1. All patients will be started on ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018195-33 | Sponsor Protocol Number: D1443L00079 | Start Date*: 2010-05-11 | |||||||||||
Sponsor Name:Centro de Investigación Biomédica en Red en el Área de Salud Mental (CIBERSAM) | |||||||||||||
Full Title: Eficacia de quetiapina de liberación prolongada vs. placebo como terapia coadyuvante al tratamiento eutimizante en el control de los síntomas subsindrómicos del trastorno bipolar | |||||||||||||
Medical condition: Terapia coadyuvante en el control de los síntomas subsindrómicos del trastorno bipolar | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003803-31 | Sponsor Protocol Number: PIO-BP | Start Date*: 2015-05-29 | |||||||||||
Sponsor Name:Hospital Universitario Araba (Sede Santiago) | |||||||||||||
Full Title: Adjunct pioglitazone IN THE TREATMENT OF BIPOLAR DISORDER. | |||||||||||||
Medical condition: Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010276-16 | Sponsor Protocol Number: F1D-MC-HGMX | Start Date*: 2009-11-19 | ||||||||||||||||
Sponsor Name:Eli Lilly | ||||||||||||||||||
Full Title: A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia | ||||||||||||||||||
Medical condition: Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004023-24 | Sponsor Protocol Number: PRETEC-EPO | Start Date*: 2016-12-15 | ||||||||||||||||
Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet | ||||||||||||||||||
Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO) | ||||||||||||||||||
Medical condition: Bipolar disorder and unipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002263-26 | Sponsor Protocol Number: P180101 | Start Date*: 2019-05-13 | |||||||||||
Sponsor Name:DRCI APHP | |||||||||||||
Full Title: Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder | |||||||||||||
Medical condition: Adult individuals with bipolar I disorders who initiate lithium treatment based on the decision of themselves and their clinician | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Completed) DE (Prematurely Ended) DK (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001337-40 | Sponsor Protocol Number: BXCL501-105 | Start Date*: 2021-10-05 | |||||||||||||||||||||
Sponsor Name:BioXcel Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER | |||||||||||||||||||||||
Medical condition: Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subjec... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003038-34 | Sponsor Protocol Number: D1002001 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression | |||||||||||||
Medical condition: Bipolar I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000456-29 | Sponsor Protocol Number: FCD-ADA-1401 | Start Date*: 2014-10-31 | ||||||||||||||||
Sponsor Name:Ferrer Internacional, S.A. | ||||||||||||||||||
Full Title: EFFICACY AND SAFETY OF INHALED LOXAPINE COMPARED WITH IM ANTIPSYCHOTIC IN ACUTELY AGITATED PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER | ||||||||||||||||||
Medical condition: SCHIZOPHRENIA AND BIPOLAR DISORDER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) ES (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-019778-34 | Sponsor Protocol Number: D1050292 | Start Date*: 2011-03-14 | |||||||||||
Sponsor Name:Sunovion, Inc. | |||||||||||||
Full Title: A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS ... | |||||||||||||
Medical condition: Bipolar disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007457-13 | Sponsor Protocol Number: D1050236 | Start Date*: 2009-10-21 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression | |||||||||||||
Medical condition: Bipolar depression | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007482-23 | Sponsor Protocol Number: D1050235 | Start Date*: 2009-10-21 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression | |||||||||||||
Medical condition: Bipolar depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003039-31 | Sponsor Protocol Number: D1002002 | Start Date*: 2015-08-20 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd. | |||||||||||||
Full Title: A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder | |||||||||||||
Medical condition: Bipolar I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002126-24 | Sponsor Protocol Number: SEP380-301 | Start Date*: 2022-02-02 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
Medical condition: Major Depressive Episode Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002317-58 | Sponsor Protocol Number: ITI-007-404 | Start Date*: 2018-03-09 | |||||||||||
Sponsor Name:Intra-Cellular Therapies, Inc. (ITI) | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes... | |||||||||||||
Medical condition: Bipolar I or Bipolar II Disorder (Bipolar Depression) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018409-13 | Sponsor Protocol Number: P05691 | Start Date*: 2012-08-23 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering | |||||||||||||
Full Title: A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experie... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
